Physician profile
Danielle D Cooper
NPI 1740256643
$2,136.30
in general payments reported to CMS, 2019-2025
20 companies · $562 in 2025
The $562 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $42.80 · 2022: $258 · 2023: $391 · 2024: $758 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,710.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $334.64 | 2022-2024 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $294.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $241.93 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $229.04 | 2019-2025 | |
| Abbvie INC. | $225.45 | 2022-2025 | Ubrelvy |
| Amgen INC. | $182.61 | 2020-2024 | Prolia, Evenity |
| Exact Sciences Corporation | $138.80 | 2024-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $87.64 | 2024-2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $77.98 | 2022-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $75.19 | 2019-2024 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $37.02 | 2019-2023 | |
| Dynavax Technologies Corporation | $36.96 | 2023 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $27.56 | 2024-2025 | Voquezna |
| Hologic Sales and Service, LLC | $24.05 | 2025 | Aptima |
| Radius Health, INC. | $23.10 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $22.85 | 2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.17 | 2022 | |
| Merck Sharp & Dohme LLC | $19.77 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Dexcom, INC. | $18.75 | 2024 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $17.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.